{"ok":true,"trend":{"id":715586,"platform":"news","region":"global","key":"insilico medicine nominates ai-designed gipr antagonist ism1354 for obesity and metabolic disease","title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease","url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxObXBCVWlFOHNJSFEyZWVaalFqRF8zaXlTZWVTOTFiZW9NQmdDWXl0TnJLejdUeHFCY0ZKUjI0ME50S2JfWUlRMzM3cFgweU0ydzVoaThkZ0tOY3gtM3d4bTVIRERQelVxbzlRZURTSmUzNmVlMkxtclJCTGxReGRrVXllbXFSaFl5RnV0NzhqQVRQMXhKWEVnZ2Vab25fN1MzaEFObXg1Ul8xdjhhd3NzaklLVnhNcEQyTXJ2VmdVUGtNa05PNy1LVg?oc=5","first_seen":"2026-10-02T09:05:52.360127Z","last_seen":"2026-10-02T14:34:35.057330Z","last_rank":9,"peak_rank":2,"last_volume":null,"peak_volume":0,"seen_count":5,"score":0.84921875,"category_hint":"medicine","section":"health","category":"medicine","summary":"Insilico Medicine has nominated ISM1354, a GIPR antagonist designed using its artificial intelligence drug discovery platform, as a preclinical candidate for obesity and related metabolic diseases. The company says the molecule was generated and optimised end-to-end with generative AI tools. It adds to a growing slate of AI-discovered drugs moving toward clinical development, as pharmaceutical firms race to apply machine learning to the booming obesity treatment market.","why":"AI-designed drugs for obesity are attracting attention amid intense industry competition in the weight-loss treatment space.","tone":"neutral","entities":["Insilico Medicine","ISM1354","GIPR"],"summarized_at":"2026-10-02T15:09:04.842827Z","meta":{"via":"scan","lang":"en","term":"medicine","source":"Drug Target Review","published":"Fri, 02 Oct 2026 08:37:57 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Insilico Medicine unveils AI-designed obesity drug candidate ISM1354","section_name":"Health","category_name":"Medicine","timeline":[{"captured_at":"2026-10-02T09:05:52.360127Z","rank":2,"volume":null},{"captured_at":"2026-10-02T10:28:11.964561Z","rank":5,"volume":null},{"captured_at":"2026-10-02T11:50:15.567101Z","rank":6,"volume":null},{"captured_at":"2026-10-02T13:12:11.882320Z","rank":6,"volume":null},{"captured_at":"2026-10-02T14:34:35.057330Z","rank":9,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxObXBCVWlFOHNJSFEyZWVaalFqRF8zaXlTZWVTOTFiZW9NQmdDWXl0TnJLejdUeHFCY0ZKUjI0ME50S2JfWUlRMzM3cFgweU0ydzVoaThkZ0tOY3gtM3d4bTVIRERQelVxbzlRZURTSmUzNmVlMkxtclJCTGxReGRrVXllbXFSaFl5RnV0NzhqQVRQMXhKWEVnZ2Vab25fN1MzaEFObXg1Ul8xdjhhd3NzaklLVnhNcEQyTXJ2VmdVUGtNa05PNy1LVg?oc=5","author":"Drug Target Review","title":"Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease","snippet":null,"posted_at":"2026-10-02T08:37:57Z","likes":null}],"elsewhere":[],"window":"7d"}}